Novel target found for CDKL5 deficiency disorder
Scientists have discovered that increasing the levels of the CDKL2 enzyme could stop CDD symptoms developing or worsening.
List view / Grid view
A drug target is anything within a living organism to which a drug is directed and/or binds, resulting in a change in its behaviour or function.
Scientists have discovered that increasing the levels of the CDKL2 enzyme could stop CDD symptoms developing or worsening.
A mechanism by which the immune system influences central nervous system function and behaviour has been discovered.
This eBook explores a new means to perform single-cell functional analysis. Uncover the Xdrop®single-cell format workflow with its ability to help identify, quantify, and comprehend immune cell functions at the individual cellular level.
New insights about young-onset CRC tumour-related bacteria could lead to new diagnostic markers and therapeutic targets.
Researchers found that resolvinT4 restores protective macrophage biological activities in rheumatoid arthritis patients.
Explore an MEA workflow used to validate the ALS-relevant phenotype of precision reprogrammed iPSC-derived neuronal disease models of ALS from bit.bio
A new study has identified targets to refine diagnostic tests, track disease progression, and discover more effective therapies.
Learn about the different types of multiplexed imaging available, as well as their applications, benefits and disadvantages.
This app note explores a groundbreaking multiplex immunodetection approach to identify cancer stem cell niches within hepatocellular carcinoma (HCC).
The new study suggests that this gene therapy method may combat ARVC in both early and more advanced stages of the condition.
How pure consistent and functional lower motor neurons can be precision reprogrammed from iPSCs for motor neuron disease research and drug discovery.
Inhibition of FAM3C expression in cancer-associated adipocytes during early tumour development holds promise as a novel treatment approach.
The new study’s findings suggest that CRS can be treated with an IL-6 receptor antibody that has a short half-life.
Liver-specific knockdown of TRPC3 enhanced alcohol's inhibitory effect on AMPK through a mechanism of Ca2+-dependent CaMKK2 activation.
Researchers discover a key metabolic process that cancer cells use to grow in a nutrient deprived environment, which could be a new target.